Loading...

EBS EMERGENT BIOSOLUTIONS INC Company Mergers 8-K Filing

MRGN

BS

EMERGENT BIOSOLUTIONS INC

(EBS)

2025 8-K

FDA Approval Received

Board Member Retirement

Quarterly Results Report

Contract Modification

Contract Enhancement

Financial Statements

Contract Renewal

Civil, Criminal Litigations

Financial Statements

Earnings Announcement

Investor Presentation

Commercial Rights Agreement

Contract Modifications

Earnings Announcement

Credit Agreement

Equity Issuance

Term Loan Agreement

Financial Results Announcement

Settlement Agreement with J...

Contract Modifications

Annual Meeting Approval

Contract Modification and F...

Restructuring Plan

Entry into Material Definit...

Amendment of Senior Secured...

Appointment of CEO

Participation in Conference

Contract Option

Restatement of Financial Re...

Results of Operations and F...

Departure of Directors

Restructuring Plan and Depa...

Compensation Agreements

Post-Market Approval

Management Change

Amendment to Stock Incentiv...

Contract Modification

Amendment and Extension of ...

Completion of Acquisition o...

Agreement Amendment

FDA Approval of NARCAN Nasa...

Departure of Chief Strategy...

Sale of Travel Health Business

Financial Results and Restr...

External Links:

On September 5, 2025, Emergent BioSolutions Inc. received a $56 million contract modification from the U.S. ASPR to supply the ACAM2000 smallpox vaccine by December 31, 2025. This is part of an existing 10-year contract with the government.

AI Assistant

EMERGENT BIOSOLUTIONS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.